ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0643

Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare

Mary Horton1, Joanne Nitithalm2, Kimberly Taylor3, Laura Trupin4, Patricia Katz5, Jinoos Yazdany6, Maria Dall'Era7, Lisa Barcellos8, Lindsey Criswell9 and Cristina M Lanata10, 1NIH/NHGRI, Oakland, CA, 2NIH/NHGRI, Bethesda, MD, 3University of Californi, San Francisco, San Francisco, CA, 4UC San Francisco, San Francisco, CA, 5UCSF, San Rafael, CA, 6UCSF, San Francisco, CA, 7University of California, Division of Rheumatology, San Francisco, CA, 8School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, 9National Human Genome Research Institute, NIH, Bethesda, MD, 10NIH/NHGRI, Washington, DC

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Epigenetics, genomics, Statistical methods, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The objective of this study was to use DNA methylation from flaring SLE patients to identify distinct biological subtypes of SLE associated with disease activity

Methods: Fifty-three SLE flaring patients recruited during routine clinical care were studied. A flare was defined by the treating rheumatologist and characterized with the SLEDAI score. Blood samples, clinical data and medication use were collected at the time of flare and approximately three months later. Genome-wide methylation profiles were generated using Illumina’s Infinium Human MethylationEPIC BeadChip. Quantile normalization and background subtraction with dye-bias normalization were performed using minfi and methylation sites (CpGs) with high detection p-values, cross-reactive probes, and those measuring genetic variants were excluded. Differentially methylated positions (DMPs) associated with SLEDAI score were identified using limma. Models accounted for the paired design and adjusted for blood cell proportions, batch, age, sex, medications, and genetic principal components. Consensus hierarchical clustering was then performed on the 5,000 most significant DMPs using methylation M-values from the highest SLEDAI visit to identify patient subgroups. Clinical features and DMPs unique to each subgroup were identified using ANOVA, chi-square, and limma. Gene ontology enrichment analysis was performed on the set of DMPs unique to each subtype.

Results: The mean SLEDAI score among flaring samples was 10.2 (sd=6.3). Three clusters of patients were identified using DNA methylation data (Table 1). Mean SLEDAI was lowest for Cluster 1 (7.5 (sd=7.2)) and increased for each subsequent group (11.0 (sd=7.2) and 14.7 (sd=3.9) for Cluster 2 and Cluster 3, respectively). Cluster 2 was characterized by a higher percentage of Asians (68%) and Cluster 3 a higher percentage of Hispanics (64%). More than 100 DMPs were identified as unique for each cluster (p< 0.05). The most significant gene ontology pathways for Cluster 1 were predominantly phosphorylation processes and regulation of defense response by viruses. For Cluster 2, notable DMPs were found in EBF1 (B-cell transcription factor), C12orf66 (regulator of mTOR signaling), and SWT1 (riboendonuclease expressed in basophils). Top pathways included import into the nucleus and adrenergic receptor signaling. For Cluster 3, notable DMPs include KMT2C (methyltransferase expressed in neutrophils), RFXP3 (associated with monocyte recruitment and differentiation), ITSN2 (regulator of clathrin-coated vesicles and induction of T cell antigen receptor endocytosis), and KIAA1530 (gene involved in UV-sensitive syndrome). Pathways for Cluster 3 included synaptic transmission and several neuronal membrane pathways (Tables 2, 3).

Conclusion: Three biologically distinct subgroups of flaring SLE patients were identified using DNA methylation data. This subtyping might be used to better inform treatment decisions and targeted therapies based on relevant underlying biological pathways.

Supporting image 1

Table 1. Demographic and clinical characteristics of 53 SLE patients at clinical visit with larger SLEDAI, subset by DNA methylation cluster assignment

Supporting image 2

Table 2. Top 10 most significant SLEDAI-associated CpG sites associated with each DNA methylation cluster

Supporting image 3

Table 3. Top 10 most significant gene ontology (GO) pathways associated with each DNA methylation cluster


Disclosures: M. Horton, None; J. Nitithalm, None; K. Taylor, None; L. Trupin, None; P. Katz, None; J. Yazdany, AstraZeneca, Gilead, Bristol-Myers Squibb(BMS), Aurinia, Astra Zeneca, Pfizer; M. Dall'Era, GlaxoSmithKline (GSK), AstraZeneca, Aurinia, BMS, Amgen; L. Barcellos, None; L. Criswell, None; C. M Lanata, None.

To cite this abstract in AMA style:

Horton M, Nitithalm J, Taylor K, Trupin L, Katz P, Yazdany J, Dall'Era M, Barcellos L, Criswell L, M Lanata C. Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/subsetting-sle-patients-based-on-dna-methylation-at-the-time-of-disease-flare/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subsetting-sle-patients-based-on-dna-methylation-at-the-time-of-disease-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology